SRC and non-small cell lung carcinoma: We have previously shown effective suppression of IGF1R or Src phosphorylation in NSCLC cell lines by treatment with the small molecule tyrosine kinase inhibitors linsitinib (1 μM) or dasatinib (100 nM), respectively [19].